Oppenheimer initiated coverage on shares of Synlogic (NASDAQ:SYBX) in a research report released on Friday morning. The firm issued an outperform rating and a $18.00 target price on the biotechnology company’s stock. Oppenheimer also issued estimates for Synlogic’s Q2 2018 earnings at ($0.51) EPS, Q3 2018 earnings at ($0.53) EPS, Q4 2018 earnings at ($0.55) EPS, FY2019 earnings at ($2.15) EPS and FY2020 earnings at ($2.73) EPS.
Several other brokerages have also commented on SYBX. HC Wainwright set a $20.00 price objective on shares of Synlogic and gave the stock a buy rating in a report on Friday, May 11th. ValuEngine upgraded shares of Synlogic from a strong sell rating to a sell rating in a report on Friday, April 27th. Zacks Investment Research lowered shares of Synlogic from a hold rating to a sell rating in a report on Wednesday, May 16th. Finally, Piper Jaffray Companies restated a buy rating and issued a $15.00 price objective on shares of Synlogic in a report on Monday, April 9th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has an average rating of Buy and an average target price of $18.17.
Shares of Synlogic opened at $9.83 on Friday, MarketBeat reports. Synlogic has a one year low of $8.73 and a one year high of $23.00. The company has a market capitalization of $250.17 million, a PE ratio of -1.67 and a beta of 1.83.
Synlogic (NASDAQ:SYBX) last issued its quarterly earnings data on Tuesday, May 15th. The biotechnology company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.18. The company had revenue of $0.35 million during the quarter, compared to analyst estimates of $0.21 million. research analysts anticipate that Synlogic will post -2.25 earnings per share for the current year.
In other Synlogic news, insider Paul Francis Miller sold 3,000 shares of the stock in a transaction that occurred on Wednesday, June 20th. The shares were sold at an average price of $9.77, for a total transaction of $29,310.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 23.30% of the stock is owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd acquired a new stake in Synlogic during the 1st quarter worth approximately $120,000. Element Capital Management LLC acquired a new stake in Synlogic during the 1st quarter worth approximately $182,000. Sofinnova Ventures Inc acquired a new stake in Synlogic during the 1st quarter worth approximately $5,393,000. Farallon Capital Management LLC acquired a new stake in Synlogic during the 1st quarter worth approximately $9,146,000. Finally, DRW Securities LLC acquired a new stake in shares of Synlogic in the 1st quarter valued at $178,000. Institutional investors own 63.54% of the company’s stock.
Synlogic Company Profile
Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.